ancitabine / Generic mfg. - LARVOL DELTA

Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity. (PubMed, J Virol) - "Through screening of an FDA-approved compound library, we identify the small-molecule cyclocytidine hydrochloride (Cyclo-C) as a potent inhibitor of PEDV replication that acts by stabilizing the peroxisomal biogenesis factor PEX13, a previously unrecognized host restriction factor...In infected neonatal piglets, Cyclo-C reduced mortality and viral loads while protecting intestinal integrity. This study provides proof of concept that targeting peroxisomal immune regulation is a viable antiviral strategy and identifies Cyclo-C as a promising candidate for treating PEDV infection."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • PEX13

High-throughput screening uncloaks actionable compounds for ttmv::rara AML (ASH 2025) - "Clinical data from ourmulticenter cohorts (n=25) revealed that 20 patients showed initial response to conventional APLregimens including all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), but paradoxicallydemonstrated poor disease control, evidenced by the event-free survival (EFS) was 53.6% with relapse-free survival (RFS) exceeding to 53.8% beyond 2 years...Dose-response curves revealed significant half maximalinhibitory concentration (IC50) reductions (>5-fold) relative to vector controls in 5/10 candidates:anagrelide (phosphodiesterase III inhibitor), lenvatinib (multi-kinase inhibitor), cytarabine (nucleosideanalog), cyclocytidine (prodrug of cytarabine), and tandutinib (FLT3 inhibitor). Crucially, the establishedAPL therapies ATRA and ATO, as well as the widely used BCL2 inhibitor venetoclax, showed no significantreduction in IC50, suggesting a possible link to the clinical observation of rapid relapse in this disease.Our findings establish the human..."

Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • CD33 • CD34 • CEACAM8 • FLT3 • ITGAM • PTPRC

Proteomic and metabolomic analysis of serum in women infected with COVID-19 during late pregnancy. (PubMed, Front Immunol) - "Metabolomics analysis revealed key altered metabolites, including 1-(7-methoxy-2-oxo-2H-chromen-8-yl)-3-methyl-2-oxobutylacetate, 5-(hydroxymethyl) -4-methoxy-2,5-dihydrofuran-2-one, and cyclocytidine, which were involved in the riboflavin metabolism, the phenylalanine, tyrosine and tryptophan biosynthesis, and the arginine biosynthesis...Our comprehensive omics data elucidating the molecular mechanisms underlying SARS-CoV-2 infection in women during late pregnancy. These findings offer novel insights and potential targets for future investigations into the impact of SARS-CoV-2 infection on maternal and infant health."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • SAA1 • SAA2